Artesunate-mefl oquine: a malaria treatment for African children?
Artesunate-mefl oquine is one of fi ve artemisinin-based combination therapy (ACT) formulations recommended by WHO for the treatment of uncomplicated falciparum malaria worldwide. 1 The scaled-up deployment of ACTs in Africa during the past 10 years, and their substitution in place of failing monotherapies, particularly chloroquine and sulfadoxine-pyrimethamine, has con tributed to the reduction in levels of malaria trans mission, 2 and currently, no other therapy is as eff ective. The artemisinin component has a short-lived but powerful action to reduce the malaria parasite count, reducing the chance of severe disease and death and onward transmission of the infection. The partner antimalarial drug has a slower elimination half-life, producing a post-treatment prophylactic eff ect, which conveys additional benefi t in high-endemic settings. Alarmingly, the emergence of artemisinin-tolerant parasites in south-east Asia is now well documented. One strategy to prevent the spread of artemisinin resistance is to have a range of ACT formulations available for use in a given setting, so that the parasite population is not overexposed to the pressure of any single drug combination. 1 Despite its recommendation for use in Africa, artesunate-mefl oquine is absent from treatment guidelines and unregistered in many African countries. Policy makers need to be sure that their decisions regarding drug deployment are well informed. Extensive use of artesunate-mefl oquine and mefl oquine monotherapy, mainly in southeast Asia, has shown that notable drug-attributed eff ects are early vomiting, during the treatment course, and self-limiting neuro psychiatric eff ects, most commonly dizziness and insomnia. [3] [4] [5] [6] [7] Concerns about a paucity of data on tolerance and effi cacy of artesunate-mefl oquine in children, who carry the greatest burden of malaria cases in Africa, might contribute to the rarity of its use.
In The Lancet Infectious Diseases, Sodiomon Sirima and colleagues 8 describe the fi ndings of a phase 4, multicentre, open-label trial assessing non-inferiority of the effi cacy and safety of a fi xed-dose formulation of artesunate-mefl oquine (developed by the Drugs for Neglected Diseases initiative and the Brazilian public health laboratory Farmanguinhos in 2002). This formulation has age-based, rather than weight-based dosing, facilitating its use in resource-poor settings. The once-daily dose is expected to promote adherence and to reduce the possibility of dosing errors. The comparator drug was artemether-lumefantrine, which is the ACT used most commonly in Africa.
With 944 participants from Tanzania, Burkina Faso, and Kenya, aged between 6·0 months and 59·8 months, this is the largest study assessing artesunate-mefl oquine in African children with uncomplicated falciparum malaria. The prolonged follow-up period of 63 days incorporated the long elimination half-life (2-3 weeks) of mefl oquine. In the per-protocol analysis, the PCR-corrected rate of adequate clinical and parasitological response at 63 days was 90·9% (370 of 407 patients) in the artesunate-mefl oquine group and 89·7% (365 of 407 patients) in the artemether-lumefantrine group. Artesunate-mefl oquine was non-inferior to artemetherlumefantrine (treatment diff erence 1·23%, 95% CI -2·84% to 5·29%) and both parasite and fever clearance times were indistinguishable between groups after 48 h, with some suggestion that initially rates were faster in the artesunate-mefl oquine group. There was no increase in microscopic gametocyte clearance rate with artesunate-mefl oquine and re-infection was delayed longer with artesunate-mefl oquine than with artemether-lumefantrine, as reported previously in a similar setting. 9 The investigators found no diff erence between treatment groups in the frequency of early vomiting (16% on any study day), and it reduced during the 3-day course. This result accords with fi ndings in other populations that vomiting is less frequent if the 25 mg/kg dose of mefl oquine is divided evenly over the 3 treatment days. 6 Few neurological adverse events occurred in either treatment group. This fi nding has to be put into context. As Sirima and colleagues note, the trial was not powered for specifi c safety outcomes. During the long period of safety follow-up, 63 days, plus three more visits over 63 days after treatment failure, neuropsychiatric adverse event monitoring was encouraged, but it was not systematic. In children younger than 5 years, standardised assessment of neuropsychiatric status is challenging, not least logistically, in a trial of this size. 3, 10 Detailed assessment was done in young children (with mean age 3 years) in a single-arm study in Cameroon, 5 in which 3·8% of 213 children had a mild-to-moderate drug-related neuropsychiatric event after treatment with artesunate-mefl oquine, the most common of which was sleep disorder. Reduced susceptibility to mefl oquine has been documented in African parasites, particularly in west Africa. 11 Consistent surveillance of molecular resistance markers, in-vitro susceptibility, and in-vivo treatment responses will be important when monitoring the eff ect of introducing the fi xed-dose combination. Additional pharmacokinetic data from Africa could complement the current consensus that adjustment of the dose of mefl oquine in children is not necessary. 4 Three issues merit operational consideration in the African setting of higher malaria transmission. First, there is an increased risk of neuropsychiatric eff ects if the treatment course of artesunate-mefl oquine is repeated within 60 days. 1, 12 Indeed, Sirima and colleagues report that 444 (48%) of 933 children in their study were retreated with an alternative rescue treatment within 63 days, similar to proportions recorded by other investigators. 13 The risk of repeated treatment should be investigated in well designed cohort studies; 13 furthermore, awareness of this risk should be incorporated in training initiatives for health-care providers. Second, because of drug interaction, 1 the eff ects of previous mefl oquine exposure on the effi cacy of artemether-lumefantrine treatment should be assessed. Finally, comparison studies exploring cost-eff ectiveness in African countries will be important.
Further complementary studies would optimise the safe delivery of a fi xed-dose combination of artesunatemefl oquine to African children, but its increased availability could off er an effi cacious treatment with rapid action and prolonged protection from re-infection; an important resource in the fi ght against malaria.
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